FILING ANALYSIS · MONDAY, NOVEMBER 9
Turn Therapeutics Inc. TTRX — 8-K: Results of Operations and Financial Condition
positive
Turn Therapeutics reported encouraging results from its Stage 1/Phase 2a trial of GX-03 in atopic dermatitis, with 59.3% of patients achieving clear or almost clear skin after four weeks, and is accelerating its Phase 2a trial of GX-03 in hidradenitis suppurativa, now expected to begin in the first quarter of 2027. The company also expects to report topline results from its Phase 2b trial in the f
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →